- Adults with acute migraine treated with intranasal lidocaine had a greater reduction in pain intensity, a higher treatment success rate, and less need for rescue medication than controls.
- Meta-analysis of 6 randomised controlled trials (n=613) assessed the efficacy and safety of intranasal lidocaine for treatment of migraines.
- Primary outcome: pain intensity measured using visual analogue scale, numerical rating scale, or verbal rating scale.
- Funding: National Institute for Health Research.
- Intranasal lidocaine vs control group showed significant decrease in pain intensity (P<.05 at: style="list-style-type:circle;">
- 5 minutes (standardised mean difference [SMD], −0.45); and
- 15 minutes (SMD, −0.41).
- higher success rates (risk ratio [RR], 3.55; P<.0001 and>
- less frequent need for rescue medication (RR, 0.59; P=.004).
- Local irritation influences the blinding of participants.
Coauthored with Chitra Ravi, MPharm